Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Disarm Therapeutics
Finance Watch: Lightstone Ventures Closes $375m Fund To Back Early Stage Biotechs
Private Company Edition: Recent biopharma venture capital financings add up to $1.7bn, including a $135m crossover round for HilleVax after spinning out of Takeda in July to advance a norovirus vaccine, Skyhawk’s $133m in fresh funding and Obsidian’s $115m series B round.
Lilly Tries New Neuro Approach With Disarm Buyout
Deal Snapshot: Lilly bets $135m on biotech’s preclinical SARM1 inhibitor program, seeing potential in peripheral neuropathy and possibly some bigger targets in neurology like MS and ALS.
- Drug Discovery Tools
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.